Epidemiology & Surveillance, Canadian Blood Services, Ottawa, ON, Canada.
School of Epidemiology & Public Health, University of Ottawa, Ottawa, ON, Canada.
Can J Public Health. 2024 Aug;115(4):558-566. doi: 10.17269/s41997-024-00901-w. Epub 2024 Jul 9.
In Canada's federated healthcare system, 13 provincial and territorial jurisdictions have independent responsibility to collect data to inform health policies. During the COVID-19 pandemic (2020-2023), national and regional sero-surveys mostly drew upon existing infrastructure to quickly test specimens and collect data but required cross-jurisdiction coordination and communication.
There were 4 national and 7 regional general population SARS-CoV-2 sero-surveys. Survey methodologies varied by participant selection approaches, assay choices, and reporting structures. We analyzed Canadian pandemic sero-surveillance initiatives to identify key learnings to inform future pandemic planning.
Over a million samples were tested for SARS-CoV-2 antibodies from 2020 to 2023 but siloed in 11 distinct datasets. Most national sero-surveys had insufficient sample size to estimate regional prevalence; differences in methodology hampered cross-regional comparisons of regional sero-surveys. Only four sero-surveys included questionnaires. Sero-surveys were not directly comparable due to different assays, sampling methodologies, and time-frames. Linkage to health records occurred in three provinces only. Dried blood spots permitted sample collection in remote populations and during stay-at-home orders.
To provide timely, high-quality information for public health decision-making, routine sero-surveillance systems must be adaptable, flexible, and scalable. National capability planning should include consortiums for assay design and validation, defined mechanisms to improve test capacity, base documents for data linkage and material transfer across jurisdictions, and mechanisms for real-time communication of data. Lessons learned will inform incorporation of a robust sero-survey program into routine surveillance with strategic sampling and capacity to adapt and scale rapidly as a part of a comprehensive national pandemic response plan.
在加拿大的联邦医疗保健系统中,13 个省级和地区行政单位负责独立收集数据以制定卫生政策。在 COVID-19 大流行期间(2020-2023 年),全国和地区血清学调查主要利用现有基础设施快速检测样本和收集数据,但需要跨辖区协调和沟通。
进行了 4 项全国性和 7 项地区性一般人群 SARS-CoV-2 血清学调查。调查方法因参与者选择方法、检测选择和报告结构而异。我们分析了加拿大大流行血清学监测计划,以确定关键经验教训,为未来的大流行规划提供信息。
2020 年至 2023 年,对超过 100 万个样本进行了 SARS-CoV-2 抗体检测,但这些数据分别保存在 11 个独立的数据集中。大多数全国性血清学调查的样本量不足以估计区域性流行率;方法上的差异阻碍了地区性血清学调查的跨地区比较。只有四项血清学调查包括问卷调查。由于检测方法、采样方法和时间框架不同,血清学调查无法直接比较。只有三个省进行了与健康记录的链接。仅在三个省进行了与健康记录的链接。干血斑允许在偏远地区和居家令期间采集样本。
为了为公共卫生决策提供及时、高质量的信息,常规血清学监测系统必须具有适应性、灵活性和可扩展性。国家能力规划应包括检测设计和验证联盟、提高检测能力的明确机制、用于跨辖区数据链接和材料转移的基本文件,以及实时数据通信机制。经验教训将为将一个强大的血清学调查计划纳入常规监测提供信息,包括有策略地进行抽样,以及作为全面国家大流行应对计划的一部分,快速适应和扩大规模的能力。